Loss of phospholipase Cγ1 suppresses hepatocellular carcinogenesis through blockade of STAT3‐mediated cancer development

Eun‐Bi Seo, Hyun‐Jun Jang, Sun‐Ho Kwon, Yong‐Jin Kwon, Seul‐Ki Kim, Song‐Hee Lee, Ae Jin Jeong, Hyun Mu Shin, Yong‐Nyun Kim, Stephanie Ma, Haeryoung Kim, Yun‐Han Lee, Pann‐Ghill Suh, Sang‐Kyu Ye – 24 September 2022 – Phospholipase C gamma 1 (PLCγ1) plays an oncogenic role in several cancers, alongside its usual physiological roles. Despite studies aimed at identifying the effect of PLCγ1 on tumors, the pathogenic role of PLCγ1 in the tumorigenesis and development of hepatocellular carcinoma (HCC) remains unknown.

A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases

Michael L. Schilsky, Eve A. Roberts, Jeff M. Bronstein, Anil Dhawan, James P. Hamilton, Anne Marie Rivard, Mary Kay Washington, Karl Heinz Weiss, Paula C. Zimbrean – 23 September 2022

Silmitasertib plus gemcitabine and cisplatin first‐line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study

Mitesh J. Borad, Li‐Yuan Bai, Donald Richards, Kabir Mody, Joleen Hubbard, Sun Young Rha, John Soong, Daniel McCormick, Emmett Tse, Daniel O'Brien, Ahmad Bayat, Daniel Ahn, S. Lindsey Davis, Joon Oh. Park, Do‐Youn Oh – 23 September 2022

A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases

Michael L. Schilsky, Eve A. Roberts, Jeff M. Bronstein, Anil Dhawan, James P. Hamilton, Anne Marie Rivard, Mary Kay Washington, Karl Heinz Weiss, Paula C. Zimbrean – 22 September 2022

Serum bile acids as a prognostic biomarker in biliary atresia following Kasai portoenterostomy

Sanjiv Harpavat, Kieran Hawthorne, Kenneth D. R. Setchell, Monica Narvaez Rivas, Lisa Henn, Charlotte A. Beil, Saul J. Karpen, Vicky L. Ng, Estella M. Alonso, Jorge A. Bezerra, Stephen L. Guthery, Simon Horslen, Kathy M. Loomes, Patrick McKiernan, John C. Magee, Robert M. Merion, Jean P. Molleston, Philip Rosenthal, Richard J. Thompson, Kasper S. Wang, Ronald J. Sokol, Benjamin L. Shneider, for Childhood Liver Disease Research Network (ChiLDReN) – 20 September 2022

Fatty liver disease reverses the obesity paradox in chronic kidney disease stages 3–5: A follow‐up study of NHANES III

Jiaofeng Huang, Min Zhang, Yinlian Wu, Mingfang Wang, Yueyong Zhu, Su Lin – 19 September 2022 – High body mass index (BMI) has been associated with better survival in patients with end‐stage kidney disease. Individuals with fatty liver disease (FLD) have a higher risk of chronic kidney disease. It remains unclear whether the survival benefit of high BMI in patients with chronic kidney disease is present when there is concomitant FLD. This study used the data set from the Third American National Health and Nutrition Examination Survey and the corresponding survival data.

Subscribe to